NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

What you’re describing is exactly how advanced therapy manufacturing must be structured for commercialization. Unity Campus is not “extra” or redundant. It exists because regulators require a strict separation between development, training, and implementation preparation on one side, and licensed GMP manufacturing on the other. Sawston cannot legally perform exploratory work once the MAA is filed. That is why it is now dedicated to pure manufacturing and storage.

So the April 2025 migration of Advent staff from the old London site and from Sawston into Unity is not inefficiency. It is commercialization preparation. Unity becomes the development and training hub where Eden parameters, operator qualification, comparability work, and process refinements occur, none of which can happen inside a GMP suite. Sawston becomes the fixed, regulator-locked manufacturing site that must run the approved process exactly as submitted.

It may look expensive, but it is the only structure that allows a dendritic-cell therapy to advance from approval to scale. This compartmentalization is not optional. It is regulatory architecture in action.